4D7B

Structure of human transthyretin in complex with Tolcapone

Summary for 4D7B

• Entry DOI: 10.2210/pdb4d7b/pdb
• Descriptor: TRANSTHYRETIN, Tolcapone (3 entities in total)
• Functional Keywords: transport protein, amyloidogenesis
• Biological source: HOMO SAPIENS (HUMAN)
• Cellular location: Secreted: P02766
• Total number of polymer chains: 2
• Total formula weight: 28363.60

Authors

Gallego, P.,Sant'anna, R.O.,Ventura, S.,Reverter, D. (deposition date: 2014-11-21, release date: 2016-01-20, Last modification date: 2024-05-08)

Primary citation

Reverter, D.,Gallego, P.,Santana, R.,Ventura, S.
Repositioning Tolcapone as a Potent Inhibitor of Transthyretin Amyloidogenesis and its Associated Cellular Toxicity
Nat.Commun., 7:10787-, 2016

PubMed Abstract: Transthyretin (TTR) is a plasma homotetrameric protein implicated in fatal systemic amyloidoses. TTR tetramer dissociation precedes pathological TTR aggregation. Native state stabilizers are promising drugs to treat TTR amyloidoses. Here we repurpose tolcapone, an FDA-approved molecule for Parkinson's disease, as a potent TTR aggregation inhibitor. Tolcapone binds specifically to TTR in human plasma, stabilizes the native tetramer in vivo in mice and humans and inhibits TTR cytotoxicity. Crystal structures of tolcapone bound to wild-type TTR and to the V122I cardiomyopathy-associated variant show that it docks better into the TTR T4 pocket than tafamidis, so far the only drug on the market to treat TTR amyloidoses. These data indicate that tolcapone, already in clinical trials for familial amyloid polyneuropathy, is a strong candidate for therapeutic intervention in these diseases, including those affecting the central nervous system, for which no small-molecule therapy exists.

PubMed: 26902880
DOI: 10.1038/NCOMMS10787

Experimental method

X-RAY DIFFRACTION (1.15 Å)